

**Estradiol and levonorgestrel transdermal patch
(FemSeven Conti®)**

(No. 28/02)

Merck Pharmaceuticals

Summary of Recommendation

10 January 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for use within NHS Scotland.

RECOMMENDATION

FemSeven Conti® offers an alternative continuous combined hormone replacement therapy (HRT) for the treatment of oestrogen deficiency symptoms in postmenopausal women more than one year after menopause. It is formulated as a transdermal patch and is the first continuous combined HRT patch to allow once weekly application. It is not licensed for prophylaxis of osteoporosis.

HRT patches are in general more expensive than oral preparations.

**D H Lawson
Chairman**